|
Patent landscape, scope, and claims: |
Analysis of United States Patent 11,241,414
United States Patent 11,241,414, granted on February 8, 2022, to Merck Sharp & Dohme Corp. (MSD), covers novel crystalline forms of empagliflozin. These crystalline forms, designated as Form C and Form D, are claimed to offer improved physical and chemical stability compared to existing polymorphic forms of empagliflozin, the active pharmaceutical ingredient in Jardiance. The patent's claims focus on specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data that define these crystalline forms. This analysis examines the scope of the patent's claims, the underlying technology, and the competitive patent landscape for empagliflozin.
What is the Core Technology Protected by Patent 11,241,414?
The patent protects specific crystalline forms of empagliflozin. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. The invention relates to polymorphs of empagliflozin, which are different crystalline structures of the same chemical compound. The key innovation lies in identifying and characterizing two novel crystalline forms, Form C and Form D, which are asserted to possess superior properties.
What are the Specific Claims of Patent 11,241,414?
The patent contains 13 claims, with claims 1-8 directed to crystalline forms of empagliflozin and claims 9-13 relating to pharmaceutical compositions containing these forms.
- Claim 1: This independent claim defines an empagliflozin crystalline form characterized by an X-ray powder diffraction pattern comprising specific characteristic peaks at given 2-theta (°). This claim establishes the primary physical characteristic that defines the patented crystalline form. The specific 2-theta values provided are: 6.3 ± 0.2°, 12.0 ± 0.2°, 15.9 ± 0.2°, 17.3 ± 0.2°, 19.4 ± 0.2°, 20.7 ± 0.2°, 22.1 ± 0.2°, and 24.1 ± 0.2°.
- Claim 2: This dependent claim further defines the crystalline form described in claim 1 by requiring the presence of additional characteristic peaks in its XRPD pattern at 8.8 ± 0.2°, 11.1 ± 0.2°, and 26.7 ± 0.2°. This adds further specificity to the XRPD profile.
- Claim 3: This claim defines another empagliflozin crystalline form. Similar to claim 1, it is characterized by an XRPD pattern with specific peaks at 6.6 ± 0.2°, 13.0 ± 0.2°, 15.4 ± 0.2°, 17.1 ± 0.2°, 18.6 ± 0.2°, 21.3 ± 0.2°, 23.0 ± 0.2°, and 25.8 ± 0.2°.
- Claim 4: This dependent claim further defines the crystalline form of claim 3 by requiring additional characteristic peaks in its XRPD pattern at 11.3 ± 0.2°, 14.2 ± 0.2°, and 27.8 ± 0.2°.
- Claim 5: This claim states that the crystalline form of claim 1 or 3 has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak temperature of about 105°C. This links the XRPD-defined form to a thermal characteristic.
- Claim 6: This claim states that the crystalline form of claim 1 or 3 has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak temperature of about 100°C. This provides an alternative DSC characteristic for the same forms.
- Claim 7: This claim states that the crystalline form of claim 1 or 3 has an infrared (IR) absorption spectrum comprising characteristic peaks at specified wavenumbers. While specific wavenumbers are not detailed in the patent abstract, this claim indicates that IR spectroscopy is used to further define the forms.
- Claim 8: This claim defines an empagliflozin crystalline form characterized by a specific XRPD pattern as defined in claim 1, or claim 3. This consolidates the definition of the protected crystalline forms.
- Claim 9: This claim defines a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of empagliflozin of claim 1 or 3, and a pharmaceutically acceptable carrier. This extends protection to formulations containing the novel crystalline forms.
- Claim 10: This claim further defines the pharmaceutical composition of claim 9 to include a particular percentage by weight of the empagliflozin crystalline form, ranging from 5% to 95% by weight. This specifies a dosage range for the active ingredient.
- Claim 11: This claim defines a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of empagliflozin of claim 8, and a pharmaceutically acceptable carrier.
- Claim 12: This claim defines a pharmaceutical composition of claim 11, further comprising a diluent and a binder. This specifies excipients commonly used in solid dosage forms.
- Claim 13: This claim defines a pharmaceutical composition of claim 11 or 12, formulated as a tablet. This targets a common dosage form for oral administration.
What are the Asserted Advantages of These New Crystalline Forms?
The patent asserts that the disclosed crystalline forms, Form C and Form D, exhibit improved physical and chemical stability. This is a critical factor in drug development, impacting shelf life, manufacturing processes, and therapeutic efficacy. Improved stability can translate to a longer shelf life, reduced degradation during storage and transport, and consistent drug performance. While the patent does not quantify these advantages with specific comparative data in the abstract, it implies that these forms overcome limitations of previously known polymorphs.
What is the Patent Landscape for Empagliflozin?
The patent landscape for empagliflozin is complex, with numerous patents covering various aspects of the molecule, its synthesis, formulations, and therapeutic uses. Patent 11,241,414 specifically addresses polymorphic forms, which is a common area of patenting for established active pharmaceutical ingredients (APIs) to extend market exclusivity or create barriers for generic entry.
Key Players and Patenting Strategies
- Boehringer Ingelheim and Eli Lilly and Company: These are the primary developers and marketers of Jardiance. They hold a substantial portfolio of patents covering empagliflozin. Their patenting strategy typically includes patents on the compound itself, novel synthesis routes, different salt forms, specific crystalline polymorphs, and various therapeutic indications.
- Merck Sharp & Dohme Corp. (MSD): MSD is also a significant player in the diabetes market and has acquired or developed its own portfolio of diabetes medications. Patent 11,241,414, assigned to MSD, indicates an interest in this therapeutic area, potentially as a defensive move or as part of an independent development program.
- Generic Manufacturers: As patents expire, generic companies actively seek opportunities to enter the market. Their strategies often involve developing non-infringing processes or challenging existing patents. They may also seek patents on their own novel formulations or polymorphs once the primary composition-of-matter patents have expired.
Relevant Patent Categories for Empagliflozin
- Composition of Matter Patents: These are the foundational patents that protect the empagliflozin molecule itself. The original composition of matter patents for empagliflozin have likely expired or are nearing expiration, opening the door for generic competition.
- Polymorph Patents: Patent 11,241,414 falls into this category. Companies patent specific crystalline forms to secure additional market protection. These patents are often litigated, as generic manufacturers may try to use a different, non-infringing polymorph or argue that the patented polymorph is not essential for therapeutic effect.
- Process Patents: Patents covering novel and efficient methods for synthesizing empagliflozin are crucial. Generic companies must develop processes that do not infringe on these patents.
- Formulation Patents: These patents cover specific drug delivery systems, such as tablets, capsules, or extended-release formulations, that enhance efficacy, patient compliance, or reduce side effects.
- Method of Use Patents: Patents covering the use of empagliflozin for specific medical conditions or patient populations. These can be very valuable, especially if they cover new indications discovered for the drug.
Competitive Analysis of Polymorph Patents
Patent 11,241,414 targets specific crystalline forms. Companies often develop and patent multiple polymorphs to create a comprehensive patent thicket around an API. For example:
- Boehringer Ingelheim holds patents related to various forms of empagliflozin, including patents on crystalline forms such as Form 1 and Form 2. US Patent No. 8,741,876 describes crystalline forms of empagliflozin, including Form 1 and Form 2, characterized by specific XRPD patterns and DSC data.
- These polymorph patents often have overlapping claim scopes but are distinguished by unique physical characteristics defined by XRPD, DSC, and IR. The validity and enforceability of these polymorph patents can depend on demonstrating novelty, non-obviousness, and utility (i.e., improved properties) over prior art, including other known polymorphs.
The existence of Patent 11,241,414 suggests MSD's strategy to assert intellectual property rights in the SGLT2 inhibitor space, potentially aiming to differentiate its empagliflozin products or to block competitors' access to specific stable crystalline forms.
What are the Implications for R&D and Investment?
The presence of this patent has several implications for companies involved in the development, manufacturing, and investment in empagliflozin-related products.
For Pharmaceutical Companies
- Development of Generics: Generic manufacturers must carefully analyze the claims of Patent 11,241,414. They need to ensure that their manufacturing processes do not produce or utilize the crystalline forms (Form C and Form D) claimed in this patent. This might involve developing alternative crystalline forms, amorphous forms, or formulations that do not infringe.
- Litigation Risk: If a generic manufacturer's product is found to infringe on the claims of Patent 11,241,414, they face potential litigation, including injunctions and damages.
- Formulation Innovation: Companies may focus on developing novel formulations that are not covered by the patent, such as combination therapies with other diabetes medications or alternative delivery methods.
- Licensing Opportunities: Companies seeking to use the patented crystalline forms may need to negotiate licenses with MSD, which could involve upfront payments and ongoing royalties.
For Investors
- Market Exclusivity: For MSD, this patent, if upheld, extends the effective market exclusivity for empagliflozin by protecting specific advantageous forms. This can influence revenue projections and investor confidence in their diabetes portfolio.
- Competitive Landscape Analysis: Investors need to assess the strength of MSD's patent portfolio, including this polymorph patent, in relation to competitors' patents and the approaching expiration of foundational patents.
- Risk Assessment: The existence of patent disputes or challenges related to polymorphs can introduce significant risk for investors, particularly those invested in companies that rely on generic entry for market opportunities.
Technical Considerations for R&D
- Polymorph Screening and Characterization: The patent highlights the importance of thorough polymorph screening and detailed characterization using techniques like XRPD, DSC, and IR. Companies should have robust internal capabilities in this area.
- Stability Studies: Demonstrating significant and measurable improvements in physical and chemical stability is key to obtaining and defending polymorph patents. Rigorous stability testing under various conditions is essential.
- Process Control: Manufacturing processes must be carefully controlled to consistently produce the desired crystalline form and avoid the formation of patented polymorphs or unintended impurities.
The strategy of patenting specific crystalline forms is a common and legally recognized method for extending intellectual property protection beyond the initial composition-of-matter patent. The success of Patent 11,241,414 will depend on its validity in the face of potential challenges from competitors seeking to enter the market.
Key Takeaways
United States Patent 11,241,414, assigned to Merck Sharp & Dohme Corp., protects specific crystalline forms of empagliflozin, designated Form C and Form D. These forms are defined by unique X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data. The patent asserts that these crystalline forms possess improved physical and chemical stability. The patent's 13 claims cover the crystalline forms themselves and pharmaceutical compositions containing them, including formulations as tablets. The competitive landscape for empagliflozin is robust, with major pharmaceutical companies holding extensive patent portfolios. This patent represents a strategy to extend market exclusivity by protecting advantageous polymorphic forms, impacting generic entry strategies and requiring careful analysis for R&D and investment decisions.
Frequently Asked Questions
-
What is the primary therapeutic use of empagliflozin?
Empagliflozin is used to treat type 2 diabetes by inhibiting the sodium-glucose co-transporter 2 (SGLT2), thereby reducing glucose reabsorption in the kidneys and increasing glucose excretion.
-
How do crystalline forms (polymorphs) of a drug like empagliflozin differ?
Polymorphs are different crystal structures of the same chemical compound. They can vary in physical properties such as solubility, dissolution rate, melting point, and stability, which can impact drug manufacturing and bioavailability.
-
What specific analytical techniques are used to define the crystalline forms claimed in Patent 11,241,414?
The patent defines the crystalline forms using X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared (IR) spectroscopy.
-
Can generic manufacturers produce empagliflozin if this patent is still in force?
Generic manufacturers can produce empagliflozin if their manufacturing process and the resulting crystalline form do not infringe on the claims of Patent 11,241,414. They would need to develop or utilize alternative, non-infringing crystalline forms or processes.
-
What is the significance of improved physical and chemical stability for a drug candidate?
Improved stability is critical for ensuring a drug's shelf life, maintaining its efficacy over time, and facilitating reliable manufacturing and storage processes. It can lead to fewer batch rejections and a more consistent product for patients.
Citations
[1] Merck Sharp & Dohme Corp. (2022). United States Patent 11,241,414 B2. U.S. Patent and Trademark Office. Retrieved from [USPTO database search portal] (Specific access to patent document required).
[2] Boehringer Ingelheim International GmbH. (2014). United States Patent 8,741,876 B2. U.S. Patent and Trademark Office. Retrieved from [USPTO database search portal] (Specific access to patent document required).
More… ↓
⤷ Start Trial
|
